T1	PROC 47 62	estudio clínico
#1	AnnotatorNotes T1	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T2	PROC 89 100	tratamiento
#2	AnnotatorNotes T2	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T3	CHEM 105 116	amivantamab
T4	CHEM 119 129	lazertinib
T5	CHEM 134 145	bevacizumab
#3	AnnotatorNotes T5	C0796392; bevacizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T6	LIVB 150 158	personas
#4	AnnotatorNotes T6	C0027361; Persons; Population Group
T7	PROC 159 173	diagnosticadas
#5	AnnotatorNotes T7	C0011900; Diagnosis; Diagnostic Procedure
T8	DISO 178 217	cáncer de pulmón de células no pequeñas
#6	AnnotatorNotes T8	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T9	Neg_cue 206 208	no
T10	Negated 209 217	pequeñas
T11	DISO 219 224	CPCNP
#7	AnnotatorNotes T11	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T12	DISO 250 282	cambio (mutación) en el gen EGFR
T13	ANAT 310 327	partes del cuerpo
T14	PROC 350 361	tratamiento
#8	AnnotatorNotes T14	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T15	CHEM 366 377	osimertinib
#9	AnnotatorNotes T15	C4058811; osimertinib; Organic Chemical · Pharmacologic Substance
T16	CHEM 380 390	lazertinib
T17	PROC 412 460	Estudio de fase II, con un grupo y multicéntrico
T18	CHEM 464 475	amivantamab
T19	CHEM 477 487	lazertinib
T20	CHEM 490 501	bevacizumab
#10	AnnotatorNotes T20	C0796392; bevacizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T21	LIVB 505 514	pacientes
#11	AnnotatorNotes T21	C0030705; Patients; Patient or Disabled Group
T22	DISO 519 532	CPNM avanzado
#12	AnnotatorNotes T22	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T23	DISO 537 553	mutación de EGFR
T24	CHEM 579 590	TKI de EGFR
T25	LIVB 641 650	Pacientes
#13	AnnotatorNotes T25	C0030705; Patients; Patient or Disabled Group
T26	DISO 655 694	cáncer de pulmón de células no pequeñas
#14	AnnotatorNotes T26	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T27	Neg_cue 683 685	no
T28	Negated 686 694	pequeñas
T29	ANAT 760 777	partes del cuerpo
T30	PROC 800 811	tratamiento
#15	AnnotatorNotes T30	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T31	CHEM 816 827	osimertinib
#16	AnnotatorNotes T31	C4058811; osimertinib; Organic Chemical · Pharmacologic Substance
T32	CHEM 830 840	lazertinib
T33	LIVB 866 875	Pacientes
#17	AnnotatorNotes T33	C0030705; Patients; Patient or Disabled Group
T34	DISO 880 894	NSCLC avanzado
#18	AnnotatorNotes T34	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T35	DISO 899 915	mutación de EGFR
T36	DISO 1005 1022	NSCLC no escamoso
T37	Neg_cue 1011 1013	no
T38	Negated 1014 1022	escamoso
T39	PROC 1034 1050	histológicamente
T40	Neg_cue 1068 1070	no
T41	PROC 1086 1105	tratamiento radical
#19	AnnotatorNotes T41	C0332316; Radical procedure; Therapeutic or Preventive Procedure
T42	Negated 1086 1105	tratamiento radical
T43	DISO 1169 1200	mutación sensibilizante de EGFR
T44	LIVB 1211 1220	pacientes
#20	AnnotatorNotes T44	C0030705; Patients; Patient or Disabled Group
T45	DISO 1358 1385	Progresión de la enfermedad
#21	AnnotatorNotes T45	C0242656; Disease Progression; Pathologic Function
T46	PROC 1397 1413	radiológicamente
T47	PROC 1420 1431	tratamiento
#22	AnnotatorNotes T47	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T48	CHEM 1443 1454	osimertinib
#23	AnnotatorNotes T48	C4058811; osimertinib; Organic Chemical · Pharmacologic Substance
T49	CHEM 1457 1467	lazertinib
T50	PROC 1472 1483	tratamiento
#24	AnnotatorNotes T50	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T51	CHEM 1488 1499	osimertinib
#25	AnnotatorNotes T51	C4058811; osimertinib; Organic Chemical · Pharmacologic Substance
T52	CHEM 1502 1512	lazertinib
T53	PROC 1526 1538	interrumpido
T54	Duration 1539 1554	al menos 8 días
T55	PROC 1623 1634	tratamiento
#26	AnnotatorNotes T55	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T56	CHEM 1639 1650	osimertinib
#27	AnnotatorNotes T56	C4058811; osimertinib; Organic Chemical · Pharmacologic Substance
T57	CHEM 1653 1663	lazertinib
T58	Duration 1705 1713	≥6 meses
T59	PROC 1725 1736	tratamiento
#28	AnnotatorNotes T59	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T60	CHEM 1741 1752	osimertinib
#29	AnnotatorNotes T60	C4058811; osimertinib; Organic Chemical · Pharmacologic Substance
T61	CHEM 1755 1765	lazertinib
T62	DISO 1771 1789	Enfermedad medible
T63	Age 1834 1842	≥18 años
T64	LIVB 1872 1881	Pacientes
#30	AnnotatorNotes T64	C0030705; Patients; Patient or Disabled Group
T65	DISO 1913 1952	carcinoma de pulmón de células pequeñas
#31	AnnotatorNotes T65	C0149925; Small cell carcinoma of lung; Neoplastic Process
T66	DISO 1954 1958	CPCP
#32	AnnotatorNotes T66	C0149925; Small cell carcinoma of lung; Neoplastic Process
T67	LIVB 1964 1973	Pacientes
#33	AnnotatorNotes T67	C0030705; Patients; Patient or Disabled Group
T68	DISO 1978 1999	metástasis cerebrales
T69	LIVB 2018 2027	pacientes
#34	AnnotatorNotes T69	C0030705; Patients; Patient or Disabled Group
T70	DISO 2032 2053	metástasis cerebrales
#35	AnnotatorNotes T70	C0220650; Metastatic malignant neoplasm to brain; Neoplastic Process | C0555278; Cerebral metastasis; Neoplastic Process
T71	PROC 2082 2090	tratadas
T72	LIVB 2141 2150	pacientes
#36	AnnotatorNotes T72	C0030705; Patients; Patient or Disabled Group
T73	PROC 2170 2193	radioterapia definitiva
#37	AnnotatorNotes T73	C0041626; Ultraviolet Therapy; Therapeutic or Preventive Procedure | C1522449; Therapeutic radiology procedure; Therapeutic or Preventive Procedure
T74	PROC 2196 2203	cirugía
#38	AnnotatorNotes T74	C0543467; Operative Surgical Procedures; Therapeutic or Preventive Procedure
T75	DISO 2208 2229	metástasis cerebrales
T76	DISO 2299 2312	asintomáticos
#39	AnnotatorNotes T76	C0231221; Asymptomatic (finding); Finding
T77	Negated 2299 2312	asintomáticos
T78	Duration 2321 2331	≥2 semanas
T79	Neg_cue 2396 2399	sin
T80	PROC 2400 2432	tratamiento con corticosteroides
T81	Negated 2416 2432	corticosteroides
T82	PROC 2452 2463	tratamiento
#40	AnnotatorNotes T82	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T83	CHEM 2468 2484	corticosteroides
T84	Dose 2488 2499	dosis bajas
T85	Dose 2501 2507	≤10 mg
T86	Frequency 2507 2511	/día
T87	CHEM 2515 2525	prednisona
#41	AnnotatorNotes T87	C0032952; prednisone; Hormone · Organic Chemical · Pharmacologic Substance
T88	Duration 2549 2567	al menos 2 semanas
T89	LIVB 2596 2605	Pacientes
#42	AnnotatorNotes T89	C0030705; Patients; Patient or Disabled Group
T90	DISO 2654 2678	enfermedad leptomeníngea
T91	LIVB 2683 2692	Pacientes
#43	AnnotatorNotes T91	C0030705; Patients; Patient or Disabled Group
T92	DISO 2697 2728	compresión de la médula espinal
#44	AnnotatorNotes T92	C0037926; Compression of spinal cord; Disease or Syndrome
T93	Neg_cue 2729 2731	no
T94	PROC 2732 2739	tratada
T95	Negated 2732 2739	tratada
T96	LIVB 2745 2754	pacientes
#45	AnnotatorNotes T96	C0030705; Patients; Patient or Disabled Group
T97	PROC 2768 2792	tratados definitivamente
T98	PROC 2797 2804	cirugía
#46	AnnotatorNotes T98	C0543467; Operative Surgical Procedures; Therapeutic or Preventive Procedure
T99	PROC 2807 2819	radioterapia
#47	AnnotatorNotes T99	C0041626; Ultraviolet Therapy; Therapeutic or Preventive Procedure | C1522449; Therapeutic radiology procedure; Therapeutic or Preventive Procedure
T100	Duration 2867 2877	≥2 semanas
T101	Neg_cue 2928 2930	no
T102	Negated 2940 2951	tratamiento
T103	Negated 2956 2972	corticosteroides
T104	Dose 3028 3039	dosis bajas
T105	Frequency 3046 3050	/día
T106	CHEM 3054 3064	prednisona
#48	AnnotatorNotes T106	C0032952; prednisone; Hormone · Organic Chemical · Pharmacologic Substance
T107	LIVB 3083 3092	Pacientes
#49	AnnotatorNotes T107	C0030705; Patients; Patient or Disabled Group
T108	DISO 3097 3113	eventos adversos
#50	AnnotatorNotes T108	C0877248; Adverse event; Pathologic Function
T109	Neg_cue 3114 3116	no
T110	Negated 3117 3126	resueltos
T111	DISO 3141 3149	alopecia
#51	AnnotatorNotes T111	C0002170; Alopecia; Disease or Syndrome | C0497378; hair loss/baldness; Pathologic Function
T112	PROC 3158 3179	terapia anticancerosa
T113	Neg_cue 3193 3195	no
T114	Negated 3205 3213	resuelto
T115	LIVB 3251 3260	Pacientes
#52	AnnotatorNotes T115	C0030705; Patients; Patient or Disabled Group
T116	PROC 3265 3297	prueba de antígeno de superficie
T117	PROC 3299 3304	HBsAg
#53	AnnotatorNotes T117	C0201477; Hepatitis B surface antigen measurement; Laboratory Procedure
T118	DISO 3320 3331	hepatitis B
#54	AnnotatorNotes T118	C0019163; Hepatitis B; Disease or Syndrome
T119	LIVB 3333 3356	virus de la hepatitis B
T120	LIVB 3358 3361	VHB
T121	Date 12 16	2021
T122	DISO 560 570	progresión
T123	DISO 920 930	progresión
T124	CHEM 934 945	TKI de EGFR
T125	PROC 1132 1149	clasificación TNM
T126	PROC 1813 1824	RECIST v1.1
T127	DISO 2000 2012	sintomáticas
T128	PROC 2128 2135	estudio
T129	DISO 2230 2242	sintomáticas
T130	Dose 3040 3046	≤10 mg
T131	PROC 2832 2850	estado neurológico
T132	DISO 702 733	mutación en un gen llamado EGFR
T133	DISO 1225 1255	deleción del exón 19 y/o L858R
T134	Negated 2400 2411	tratamiento
T135	CHEM 2956 2972	corticosteroides
T136	CHEM 3008 3024	corticosteroides
T137	PROC 2940 2951	tratamiento
T138	PROC 2992 3003	tratamiento
T139	Observation 78 84	efecto
T140	Quantifier_or_Qualifier 209 217	pequeñas
T141	Quantifier_or_Qualifier 226 234	avanzado
T142	Quantifier_or_Qualifier 291 301	diseminado
T143	Quantifier_or_Qualifier 524 532	avanzado
T144	Quantifier_or_Qualifier 598 619	de tercera generación
T145	Quantifier_or_Qualifier 686 694	pequeñas
T146	Quantifier_or_Qualifier 886 894	avanzado
T147	Quantifier_or_Qualifier 946 967	de tercera generación
T148	Result_or_Value 1052 1066	estadio IIIB/C
T149	Result_or_Value 1109 1119	estadio IV
T150	CONC 1129 1131	8ª
T151	CONC 1132 1149	clasificación TNM
T152	Observation 1592 1609	beneficio clínico
T153	Quantifier_or_Qualifier 1610 1618	objetivo
T154	CONC 1813 1825	RECIST v1.1.
T155	Observation 2093 2101	estables
T156	Observation 2109 2135	participar en este estudio
T157	Quantifier_or_Qualifier 2183 2193	definitiva
T158	Observation 2245 2255	inestables
T159	Observation 2275 2296	clínicamente estables
T160	Observation 2610 2630	antecedentes médicos
T161	Quantifier_or_Qualifier 2631 2638	activos
T162	Observation 2832 2858	estado neurológico estable
T163	Observation 3117 3126	resueltos
T164	Quantifier_or_Qualifier 3219 3227	grado ≤1
T165	CONC 3233 3246	valor inicial
T166	Result_or_Value 3306 3314	positiva
T167	Patient 150 158	personas
T168	Patient 505 514	pacientes
T169	History_of 579 582	TKI
T170	History_of 586 590	EGFR
T171	Patient 641 650	Pacientes
T172	Patient 866 875	Pacientes
T173	History_of 934 937	TKI
T174	Patient 1211 1220	pacientes
T175	History_of 1420 1431	tratamiento
T176	History_of 1443 1454	osimertinib
T177	History_of 1457 1467	lazertinib
T178	Patient 1872 1881	Pacientes
T179	Patient 1964 1973	Pacientes
T180	Patient 2018 2027	pacientes
T181	History_of 2082 2090	tratadas
T182	Patient 2141 2150	pacientes
T183	History_of 2170 2182	radioterapia
T184	History_of 2196 2203	cirugía
T185	Patient 2596 2605	Pacientes
T186	History_of 2654 2678	enfermedad leptomeníngea
T187	Patient 2683 2692	Pacientes
T188	Patient 2745 2754	pacientes
T189	Future 2906 2915	elegibles
T190	Patient 3083 3092	Pacientes
T191	History_of 3158 3179	terapia anticancerosa
T192	Patient 3251 3260	Pacientes
T193	History_of 2183 2193	definitiva
